-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $275

Benzinga·11/03/2026 14:48:19
Listen to the news
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $271 to $275.